GEMCITABINE, DEXAMETHASONE, AND CISPLATIN (GDP): EFFECTIVE AND WELL-TOLERATED SALVAGE THERAPY FOR RELAPSED/REFRACTORY HODGKIN LYMPHOMA (HL)

被引：0
|
作者：
Moccia, A. A. [1 ,2 ]
Hoskins, P. [1 ,2 ]
Klasa, R. [1 ,2 ]
Savage, K. J. [1 ,2 ]
Shenkier, T. [1 ,2 ]
Skinnider, B. [2 ,3 ]
Slack, G. [2 ,3 ]
Gascoyne, R. D. [2 ,3 ]
Connors, J. M. [1 ,2 ]
Sehn, L. H. [1 ,2 ]
机构：
[1] British Columbia Canc Agcy, Dept Med Oncol, Vancouver, BC, Canada
[2] Univ British Columbia, Vancouver, BC, Canada
[3] British Columbia Canc Agcy, Dept Pathol, Vancouver, BC, Canada
来源：
HAEMATOLOGICA | 2010年 / 95卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P097
引用
收藏
页码：S28 / S29
页数：2
相关论文
共 50 条
  • [31] Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma
    Ng, M
    Waters, J
    Cunningham, D
    Chau, I
    Horwich, A
    Hill, M
    Norman, AR
    Wotherspoon, A
    Catovsky, D
    [J]. BRITISH JOURNAL OF CANCER, 2005, 92 (08) : 1352 - 1357
  • [32] GDP (gemcitabine, dexamethasone, cisplatin) salvage therapy results in superior progression free survival compared to mini-beam prior to autologous stem cell transplantation for relapsed or refractory Hodgkin's lymphoma.
    Kuruvilla, J
    Nagy, T
    Pintilie, M
    Keating, A
    Crump, M
    [J]. BLOOD, 2004, 104 (11) : 258A - 259A
  • [33] ESHAP as salvage therapy for relapsed or refractory Hodgkin’s lymphoma
    Jorge Labrador
    Mónica Cabrero-Calvo
    Estefanía Pérez-López
    María Victoria Mateos
    Lourdes Vázquez
    María Dolores Caballero
    Ramón García-Sanz
    [J]. Annals of Hematology, 2014, 93 : 1745 - 1753
  • [34] PREDICTING RESPONSE TO SALVAGE THERAPY IN RELAPSED AND REFRACTORY HODGKIN LYMPHOMA
    Moskowitz, A. J.
    Yahalom, J.
    Maragulia, J.
    Shi, W.
    Zhang, Z.
    Moskowitz, C. H.
    [J]. HAEMATOLOGICA, 2010, 95 : S27 - S28
  • [35] ESHAP AS SALVAGE THERAPY FOR RELAPSED OR REFRACTORY HODGKIN'S LYMPHOMA
    Labrador, J.
    Cabrero-Calvo, M.
    Perez-Lopez, E.
    Lopez-Corral, L.
    Mateos, M.
    Sanchez-Guijo, F.
    Vazquez, L.
    Bastida, J.
    Lopez-Godino, O.
    Lopez-Parra, M.
    San Miguel, J.
    Caballero, M.
    Garcia-Sanz, R.
    [J]. HAEMATOLOGICA, 2013, 98 : 69 - 69
  • [36] ESHAP as salvage therapy for relapsed or refractory Hodgkin's lymphoma
    Labrador, Jorge
    Cabrero-Calvo, Monica
    Perez-Lopez, Estefania
    Victoria Mateos, Maria
    Vazquez, Lourdes
    Dolores Caballero, Maria
    Garcia-Sanz, Ramon
    [J]. ANNALS OF HEMATOLOGY, 2014, 93 (10) : 1745 - 1753
  • [37] High efficacy of BGD (bendamustine, gemcitabine, and dexamethasone) in relapsed/refractory Hodgkin Lymphoma
    Ryszard Swoboda
    Sebastian Giebel
    Wanda Knopińska-Posłuszny
    Ewa Chmielowska
    Joanna Drozd-Sokołowska
    Ewa Paszkiewicz-Kozik
    Waldemar Kulikowski
    Michał Taszner
    Włodzimierz Mendrek
    Jacek Najda
    Tomasz Czerw
    Magdalena Olszewska-Szopa
    Anna Czyż
    Agnieszka Giza
    Wojciech Spychałowicz
    Edyta Subocz
    Paweł Szwedyk
    Aleksandra Krzywon
    Agata Wilk
    Jan Maciej Zaucha
    [J]. Annals of Hematology, 2021, 100 : 1755 - 1767
  • [38] ASHAP: AN EFFECTIVE SALVAGE THERAPY FOR REFRACTORY HODGKIN LYMPHOMA
    Cakir, F. B.
    Ozulker, T.
    Ozturk, G.
    [J]. PEDIATRIC BLOOD & CANCER, 2011, 56 (05) : 890 - 890
  • [39] DIZE (dexamethasone, idarubicin, and continuous infusion of ifosfamide and etoposide):: An effective and well-tolerated new regimen for patients with relapsed lymphoma
    Reiser, M
    Schnell, R
    Straub, G
    Borchmann, P
    Wilhelm, M
    Übelacker, R
    Wörmann, B
    Münch, R
    Diehl, V
    Engert, A
    [J]. LEUKEMIA & LYMPHOMA, 1998, 31 (3-4) : 359 - 366
  • [40] Time-intensified dexamethasone/cisplatin/cytarabine:: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease
    Josting, A
    Rudolph, C
    Reiser, M
    Mapara, M
    Sieber, M
    Kirchner, HH
    Dörken, B
    Hossfeld, DK
    Diehl, V
    Engert, A
    [J]. ANNALS OF ONCOLOGY, 2002, 13 (10) : 1628 - 1635
12345